Company intelligence / Profile preview

Harmony Asset

Plymouth Meeting, Pennsylvania, United States

Ownership: Private
Development stage: Other

Overview

Harmony Biosciences is a commercial-stage pharmaceutical company with WAKIX (pitolisant) as its flagship product, FDA-approved for excessive daytime sleepiness and cataplexy in adult narcolepsy. The company reported net product revenues of $582.6 million in 2023 and projected $700-$710 million for 2024, with over 99% of revenue derived from WAKIX sales. The company has expanded its portfolio through acquisitions including Zynerba Pharmaceuticals (2023) and Epygenix (2024), though recent setbacks include a phase 3 failure for cannabidiol gel in fragile X syndrome.

Therapeutic areas: NeurologyRare Diseases
Modalities: Small moleculeTransdermal gel
Industry: Biotech

Partnerships

Blackstone (strategic financing collaboration providing up to $330 million)

Beyond the preview

Go deeper on Harmony Asset.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Harmony Asset.

Explore the full profile